Navigation Links
Personalized treatment may help some liver cancer patients
Date:10/22/2010

A more personalized treatment for people with a type of metastatic liver cancer --hepatocellular carcinoma -- may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular carcinoma (HCC) is the number three cause of cancer deaths in the world.

Hanning You, M.D., Ph.D., postdoctoral fellow, and C. Bart Rountree, M.D., assistant professor of pediatrics and pharmacology, targeted c-Met, a known receptor for hepatocyte growth factor, the substance that appears to drive liver cancer metastasis. In a pre-clinical translational study, they show that c-Met is overexpressed in metastatic liver cancer cells and is associated with a poor prognosis.

"In addition to finding that c-Met is a significant biomarker for liver cancer, we conducted an analysis of six published manuscripts and 1,051 patients," said You. "Through this analysis we demonstrated and confirmed that c-Met activation is strongly associated with poor prognosis and aggressive features in patients with liver cancer tumors."

Currently, physicians treat hepatocellular carcinoma with a "one size fits all" approach, so targeting c-Met may be an effective therapy for some patients.

"The five-year-survival of HCC is only 2 percent when diagnosed after metastasis," said Rountree. "Sorafenib, the most recently approved mediation for advanced HCC, benefits patients with an extra two months survival."

By targeting c-Met, researchers suppressed tumor growth and proliferation in a mouse model. They believe that molecular profiling will allow better treatment for the 45 percent of HCC patients who have c-Met positive tumors.

The research team is now looking to apply their findings to HCC in humans. The lab has applied to the National Cancer Institute to join a phase I trial using a c-Met inhibitor for advanced HCC.

"We are also working to build a second trial where we will establish a molecular profile of HCC patients before we start treatment, and then only give the c-Met inhibitor to the patients with a c-Met positive tumor, in effect personalizing their therapy," Rountree said.


'/>"/>

Contact: Matt Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Related medicine news :

1. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
2. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
3. Personalized medicine: Molecular imaging predicts treatment success in many cancers
4. Pilot study supports adolescent diabetes patients through personalized text messages
5. Tumor target suggests personalized treatment for melanoma
6. Advances in personalized medicine take center stage
7. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
8. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
9. Pediatric personalized medicine takes center stage at first-of-its-kind international conference
10. Personalized medicine for cancer patients in a new technology era
11. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... ... , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor Global Food ... by Hilton Hotel in Oak Brook, Illinois. The two-day event is the largest conference ... , At the seminar, IDF™ will offer samples of its Savory Bone Broth ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... clinic data for 2014. Each year, reproductive endocrinologists are required to report ... the main organization of professionals dedicated to the practice of assisted reproductive technologies ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... providers, recently announced that their founders, Dr. Gemmi and Dr. Middleberg, were asked ... 550 orthodontists around the nation. During the seminar, titled “Advancing the Biomechanics ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... Massachusetts , April 27, 2016 ... that Jeff Poulton , Chief Financial Officer, will present ... Boston, MA on Wednesday, May 04, ... audio webcast will be available on the Presentations and Webcasts ... a replay of the webcast will be available on this ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology: